Baricitinib showed limited efficacy in pediatric JIA-uveitis patients refractory to methotrexate or biologics at week 24.
New Hope for Kids with Stubborn Eye Inflammation
This open-label, active-controlled phase-3 multicenter trial enrolled 30 pediatric patients with juvenile idiopathic arthritis-associated uv…
A new drug shows early promise for children with stubborn eye inflammation who didn't respond to standard treatments, offering hope when oth…
Baricitinib maintains SALT score ≤20 in adults with severe alopecia areata over 152 weeks.
Baricitinib maintained hair regrowth in severe alopecia areata for over three years in this trial.
This phase 3 RCT evaluated continuous baricitinib in 196 adults with severe alopecia areata. At 152 weeks, 89.1% on 4 mg and 83.6% on 2 mg m…
Baricitinib kept hair growing on the scalp, eyebrows, and eyelashes for over three years in adults with severe alopecia areata who responded…
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months.
A Rheumatoid Arthritis Drug May Help Save Lungs in Crisis
This retrospective observational case series examined six consecutive patients hospitalized for acute exacerbation of rheumatoid arthritis–a…
A small study suggests a familiar arthritis pill may help calm sudden, dangerous lung flare-ups in people with rheumatoid arthritis.
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
Common arthritis and skin drugs linked to cholesterol changes, analysis finds
A systematic review and meta-analysis of 13 phase 2 and 3 RCTs involving 5,658 patients found treatment with oral JAK inhibitors (baricitini…
Common arthritis and skin drugs can raise both 'good' and 'bad' cholesterol levels, a review of nearly 4,000 patients shows.